Table 2 Association between CYP1B1 expression and clinicopathologic features.
From: Profiling of CYP4Z1 and CYP1B1 expression in bladder cancers
Characteristic | CYP1B1-positive n = 160 (76.9%) | CYP1B1-negative n = 48 (23.1%) | P value |
|---|---|---|---|
Gender | 0.223 | ||
Male (n = 166, 79.8%) | 131 (78.9%) | 35 (21.1%) | |
Female (n = 42, 20.2%) | 36 (85.7%) | 6 (14.3%) | |
Histological type | 0.002 | ||
Urothelial carcinoma (n = 160, 76.9%) | 130 (81.2%) | 30 (18.8%) | |
Squamous cell carcinoma (n = 16, 7.7%) | 14 (87.5%) | 2 (12.5%) | |
Mucinous adenocarcinoma (n = 9, 4.3%) | 8 (88.9%) | 1 (11.1%) | |
Papillary adenocarcinoma (n = 7, 3.4%) | 5 (71.4%) | 2 (28.6%) | |
Normal (n = 16, 7.7%) | 3 (18.7%) | 13 (81.3%) | |
Histological grade | |||
I (n = 67, 34.4%) | 53 (79.1%) | 14 (20.9%) | 0.003 |
II (n = 81, 42.7%) | 68 (84.0%) | 13 (16%) | |
III (n = 44, 22.9%) | 36 (81.8%) | 8 (18.2%) | |
Normal (n = 16, 7.7%) | 3 (18.7%) | 13 (81.3%) | |
Histological stage | |||
1 (n = 53, 27.6%) | 45 (84.9%) | 8 (15.1%) | 0.002 |
2 (n = 101, 52.6%) | 74 (73.3%) | 27 (26.7%) | |
3 (n = 34, 17.7%) | 34 (100%) | 0 (0%) | |
4 (n = 4, 2.1%) | 4 (100%) | 0 (0%) | |
Normal (n = 16, 7.7%) | 3 (18.7%) | 13 (81.3%) | |
TNM staging | 0.011 | ||
T1N0M0 (n = 54, 28.1%) | 47 (85.5%) | 11 (14.5%) | |
T2N0M0 (n = 101, 52.6%) | 74 (73.3%) | 27 (26.7%) | |
T3N0M0 (n = 34, 17.7%) | 34 (100%) | 0 (0%) | |
T3N1M0 (n = 2, 1.0%) | 2 (100%) | 0 (0%) | |
T3N2M0 (n = 1, 0.5%) | 1 (100%) | 0 (0%) | |
Normal (n = 16, 7.7%) | 3 (18.7%) | 13 (81.3%) | |
